$AIM
AIM ImmunoTech Inc. Stock $aim

$aim Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-K Financial Statement

#000094664415000008 Filed on March 19, 2015

Income Statement

Concept	2015 Q1	2014 Q4	2014
Revenue	$36.00K	$40.00K	$197.0K
YoY Change	-52.63%	11.11%	31.33%
Cost Of Revenue	$372.0K	$330.0K	$1.251M
YoY Change	15.17%	106.25%	1.38%
Gross Profit	-$336.0K	-$290.0K	-$1.054M
YoY Change	36.03%	141.67%	-2.77%
Gross Profit Margin	-933.33%	-725.0%	-535.03%
Selling, General & Admin	$1.910M	$1.850M	$9.057M
YoY Change	-24.8%	5.11%	17.32%
% of Gross Profit
Research & Development	$2.674M	$2.440M	$8.988M
YoY Change	14.96%	59.48%	7.51%
% of Gross Profit
Depreciation & Amortization	$180.0K	$240.0K	$665.0K
YoY Change	7.78%	4.35%	-0.89%
% of Gross Profit
Operating Expenses	$2.674M	$4.280M	$8.988M
YoY Change	14.96%	30.09%	7.51%
Operating Profit	-$4.923M	-$4.570M	-$19.10M
YoY Change	-3.7%	34.02%	11.25%
Interest Expense	$100.0K	$250.0K	$11.00K
YoY Change		47.06%	-31.25%
% of Operating Profit
Other Income/Expense, Net		$10.00K	$14.00K
YoY Change		-93.94%	-98.19%
Pretax Income	-$3.450M	-$4.460M	-$17.45M
YoY Change	-10.16%	39.38%	7.52%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.445M	-$4.460M	-$17.45M
YoY Change	-10.19%	39.59%	7.55%
Net Earnings / Revenue	-9569.44%	-11150.0%	-8857.87%
Basic Earnings Per Share
Diluted Earnings Per Share	-$8.625M	-$11.74M	-$48.93M
COMMON SHARES
Basic Shares Outstanding	215.1M shares	200.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014 Q4	2014
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.01M	$16.11M	$16.11M
YoY Change	-21.07%	-11.43%	-11.45%
Cash & Equivalents	$2.942M	$2.156M	$2.156M
Short-Term Investments	$14.06M	$13.95M	$13.95M
Other Short-Term Assets	$430.0K	$400.0K	$399.0K
YoY Change	30.3%	11.11%	10.83%
Inventory	$480.0K	$0.00	$0.00
Prepaid Expenses	$432.0K	$399.0K
Receivables			$0.00
Other Receivables			$0.00
Total Short-Term Assets	$17.92M	$16.51M	$16.51M
YoY Change	-18.14%	-11.02%	-11.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.81M	$4.601M	$11.94M
YoY Change	141.41%	-8.95%	-1.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$134.0K	$134.0K	$134.0K
YoY Change	-1.47%	-1.47%	-4.29%
Total Long-Term Assets	$12.87M	$12.93M	$12.93M
YoY Change	-1.9%	-2.87%	-2.91%
TOTAL ASSETS
Total Short-Term Assets	$17.92M	$16.51M	$16.51M
Total Long-Term Assets	$12.87M	$12.93M	$12.93M
Total Assets	$30.79M	$29.44M	$29.44M
YoY Change	-12.05%	-7.62%	-7.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.317M	$2.081M	$2.081M
YoY Change	90.39%	63.73%	63.86%
Accrued Expenses	$1.489M	$2.333M	$2.333M
YoY Change	-14.43%	89.98%	89.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$20.00K	$20.00K	$0.00
YoY Change	-33.33%	-33.33%	-100.0%
Total Short-Term Liabilities	$3.821M	$4.436M	$4.436M
YoY Change	27.88%	75.2%	75.34%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.821M	$4.436M	$4.436M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.820M	$4.436M	$4.436M
YoY Change	26.62%	72.67%	72.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$281.2M	-$277.8M
YoY Change	6.46%	6.7%
Common Stock	$308.2M	$302.9M
YoY Change	4.05%	4.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.97M	$25.00M	$25.00M
YoY Change
Total Liabilities & Shareholders Equity	$30.79M	$29.44M	$29.44M
YoY Change	-12.05%	-7.62%	-7.62%

Cashflow Statement

Concept	2015 Q1	2014 Q4	2014
OPERATING ACTIVITIES
Net Income	-$3.445M	-$4.460M	-$17.45M
YoY Change	-10.19%	39.59%	7.55%
Depreciation, Depletion And Amortization	$180.0K	$240.0K	$665.0K
YoY Change	7.78%	4.35%	-0.89%
Cash From Operating Activities	-$4.257M	-$4.030M	-$13.92M
YoY Change	47.05%	26.73%	-17.3%
INVESTING ACTIVITIES
Capital Expenditures	$47.00K	-$190.0K	$504.0K
YoY Change	-27.69%	-9.52%	-43.88%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.080M	$3.296M
YoY Change	-100.0%	-77.9%	-85.92%
Cash From Investing Activities	-$192.0K	$1.880M	$2.488M
YoY Change	8.47%	-79.57%	-88.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$5.242M		$12.82M
YoY Change	-17.9%		5047.39%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$5.235M	3.040M	$12.78M
YoY Change	-17.87%	-144.64%	-286.69%
NET CHANGE
Cash From Operating Activities	-$4.257M	-4.030M	-$13.92M
Cash From Investing Activities	-$192.0K	1.880M	$2.488M
Cash From Financing Activities	$5.235M	3.040M	$12.78M
Net Change In Cash	$786.0K	890.0K	$1.353M
YoY Change	-76.2%	-212.66%	-196.03%
FREE CASH FLOW
Cash From Operating Activities	-$4.257M	-$4.030M	-$13.92M
Capital Expenditures	$47.00K	-$190.0K	$504.0K
Free Cash Flow	-$4.304M	-$3.840M	-$14.42M
YoY Change	45.41%	29.29%	-18.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	8024000	USD
CY2013Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	17391000	USD
CY2014	heb	Funds Received From Sale Of Income Tax Net Operating Losses FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses	1126000	USD
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0000946644
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	215095559	shares
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q2	dei	Entity Public Float EntityPublicFloat	57685937	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	HEMISPHERX BIOPHARMA INC
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013Q4	heb	Accrued Production Cost AccruedProductionCost	51000	USD
CY2014Q4	heb	Accrued Production Cost AccruedProductionCost	0	USD
CY2014	heb	Beneficial Owner Percentageof Outstanding Sharesor Voting Power Held BeneficialOwnerPercentageofOutstandingSharesorVotingPowerHeld	0.2
CY2014	heb	Defined Contribution Plan Employer Matching Contribution Minimum Numberof Yearsof Employment DefinedContributionPlanEmployerMatchingContributionMinimumNumberofYearsofEmployment	P1Y
CY2014	heb	Defined Contribution Plan Employer Matching Contribution Vesting Period DefinedContributionPlanEmployerMatchingContributionVestingPeriod	P1Y
CY2014	heb	Fda Approved Product Period Until Availablefor Commercial Sales FDAApprovedProductPeriodUntilAvailableforCommercialSales	P18M
CY2014	heb	Fair Value Inputs Future Volatility Floorof Historical Stock Values FairValueInputsFutureVolatilityFloorofHistoricalStockValues	1
CY2014	heb	Fair Value Inputs Future Volatility Periodof Historical Stock Values FairValueInputsFutureVolatilityPeriodofHistoricalStockValues	P100D
CY2014	heb	Fair Value Inputs Probabilityof Triggering Put Right FairValueInputsProbabilityofTriggeringPutRight	0.01
CY2012	heb	Funds Received From Sale Of Income Tax Net Operating Losses FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses	1328000	USD
CY2013	heb	Funds Received From Sale Of Income Tax Net Operating Losses FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses	686000	USD
CY2014	heb	Income Taxes Utilizationof Operating Loss Carryforward Limitation Percentage Changein Ownership IncomeTaxesUtilizationofOperatingLossCarryforwardLimitationPercentageChangeinOwnership	0.5
CY2013	heb	Inventory Production InventoryProduction	0	USD
CY2014	heb	Inventory Production InventoryProduction	0	USD
CY2013	heb	Inventory Spoilage InventorySpoilage	453000	USD
CY2014	heb	Inventory Spoilage InventorySpoilage	0	USD
CY2012	heb	Issuance Of Common Stock For Accounts Payable And Accrued Expenses IssuanceOfCommonStockForAccountsPayableAndAccruedExpenses	384000	USD
CY2013	heb	Issuance Of Common Stock For Accounts Payable And Accrued Expenses IssuanceOfCommonStockForAccountsPayableAndAccruedExpenses	269000	USD
CY2014	heb	Issuance Of Common Stock For Accounts Payable And Accrued Expenses IssuanceOfCommonStockForAccountsPayableAndAccruedExpenses	59000	USD
CY2014	heb	Number Of Domestic Subsidiaries NumberOfDomesticSubsidiaries	3	subsidiary
CY2012Q4	heb	Numberof Officers NumberofOfficers	3	officer
CY2012	heb	Proceeds From Margin Account Loan ProceedsFromMarginAccountLoan	5356000	USD
CY2013	heb	Proceeds From Margin Account Loan ProceedsFromMarginAccountLoan	-7051000	USD
CY2014	heb	Proceeds From Margin Account Loan ProceedsFromMarginAccountLoan	0	USD
CY2012Q4	heb	Related Party Percentageof Common Stock Owned RelatedPartyPercentageofCommonStockOwned	0.0463
CY2014	heb	Share Based Compensation Plan Percentageof Common Stock Heldof Combined Entity Changein Control Trigger ShareBasedCompensationPlanPercentageofCommonStockHeldofCombinedEntityChangeinControlTrigger	0.5
CY2012	heb	Stock Issued For Settlement Of Accounts Payable StockIssuedForSettlementOfAccountsPayable	384000	USD
CY2013	heb	Stock Issued For Settlement Of Accounts Payable StockIssuedForSettlementOfAccountsPayable	269000	USD
CY2014	heb	Stock Issued For Settlement Of Accounts Payable StockIssuedForSettlementOfAccountsPayable	59000	USD
CY2013Q4	heb	Total Fair Value Of Assets And Liabilities On Recurring Basis TotalFairValueOfAssetsAndLiabilitiesOnRecurringBasis	17377000	USD
CY2014Q4	heb	Total Fair Value Of Assets And Liabilities On Recurring Basis TotalFairValueOfAssetsAndLiabilitiesOnRecurringBasis	13952000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	5928000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1271000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2081000	USD
CY2013Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	0	USD
CY2014Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	0	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1228000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2333000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1228000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2333000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	270000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	404000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4334000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5000000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-114000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-160000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	289563000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	302729000	USD
CY2012	us-gaap	Adjustment For Amortization AdjustmentForAmortization	40000	USD
CY2013	us-gaap	Adjustment For Amortization AdjustmentForAmortization	196000	USD
CY2014	us-gaap	Adjustment For Amortization AdjustmentForAmortization	477000	USD
CY2012	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	-85000	USD
CY2013	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	-281000	USD
CY2014	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	-14000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	271000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	219000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	223000	USD
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24198158	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27968158	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17486946	shares
CY2013Q4	us-gaap	Assets Assets	31867000	USD
CY2014Q4	us-gaap	Assets Assets	29440000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	18552000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	16507000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	17391000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	13952000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	17505000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	14112000	USD
CY2013	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses	0	USD
CY2014	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses	54000	USD
CY2013	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses	229000	USD
CY2014	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses	160000	USD
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	12460000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	13952000	USD
CY2013	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses	229000	USD
CY2014	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses	106000	USD
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	12460000	USD
CY2014Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	13952000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	115000	USD
CY2014	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0	USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	229000	USD
CY2014	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	160000	USD
CY2013Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0	USD
CY2013Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	1	investment
CY2014Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	2	investment
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	33000	USD
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	22000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	23000	USD
CY2014Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	0	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3103000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2212000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	803000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2156000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-891000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1409000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1353000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	168660370	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	204004818	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	168660370	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	204004818	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	168000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	204000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-17008000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-16296000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-17496000	USD
CY2013Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	7046000	USD
CY2014Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	7337000	USD
CY2012	us-gaap	Cost Of Revenue CostOfRevenue	1989000	USD
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	1234000	USD
CY2014	us-gaap	Cost Of Revenue CostOfRevenue	1251000	USD
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	20553000	USD
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	17317000	USD
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	19296000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	48624000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	52444000	USD
CY2013Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2842000	USD
CY2014Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	923000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2013Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	14000	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2013Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	378000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	45578000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	51350000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	76000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	60000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	128000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	111000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	48624000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52444000	USD
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	138000	USD
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	171000	USD
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	170000	USD
CY2014	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2014	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.15
CY2012	us-gaap	Depreciation Depreciation	643000	USD
CY2013	us-gaap	Depreciation Depreciation	671000	USD
CY2014	us-gaap	Depreciation Depreciation	665000	USD
CY2014Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	0	USD
CY2012	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	85000	USD
CY2013	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	281000	USD
CY2014	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	14000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1806000	USD
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	177000	USD
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	259000	USD
CY2014	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2012	us-gaap	Fair Value Assumptions Expected Dividend Payments FairValueAssumptionsExpectedDividendPayments	0
CY2013	us-gaap	Fair Value Assumptions Expected Dividend Payments FairValueAssumptionsExpectedDividendPayments	0
CY2014	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P17Y
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	31000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	31000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	31000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	31000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	31000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1080000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	861000	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9056000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7723000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9057000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	860000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-617000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	869000	USD
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1751000	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2167000	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1105000	USD
CY2012	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	USD
CY2013	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	71000	USD
CY2014	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	579000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2012	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-200000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	36000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	41000	USD
CY2012	us-gaap	Interest Expense InterestExpense	24000	USD
CY2013	us-gaap	Interest Expense InterestExpense	16000	USD
CY2014	us-gaap	Interest Expense InterestExpense	11000	USD
CY2012	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	24000	USD
CY2013	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	16000	USD
CY2014	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	11000	USD
CY2012	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	85000	USD
CY2013	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	143000	USD
CY2014	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	0	USD
CY2012	us-gaap	Inventory Lifo Reserve Effect On Income Net InventoryLIFOReserveEffectOnIncomeNet	1023000	USD
CY2013	us-gaap	Inventory Lifo Reserve Effect On Income Net InventoryLIFOReserveEffectOnIncomeNet	453000	USD
CY2014	us-gaap	Inventory Lifo Reserve Effect On Income Net InventoryLIFOReserveEffectOnIncomeNet	0	USD
CY2012Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	453000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2013Q4	us-gaap	Liabilities Liabilities	2569000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	4436000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31867000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29440000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2532000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4436000	USD
CY2012	us-gaap	Marketable Securities Realized Gain Loss Other Than Temporary Impairments Amount MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount	9000	USD
CY2013	us-gaap	Marketable Securities Realized Gain Loss Other Than Temporary Impairments Amount MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount	800000	USD
CY2014	us-gaap	Marketable Securities Realized Gain Loss Other Than Temporary Impairments Amount MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount	145000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28312000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6847000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12783000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16067000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22268000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2488000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13136000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16830000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13918000	USD
CY2014	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5755000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	898000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	504000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012	us-gaap	Officers Compensation OfficersCompensation	2578000	USD
CY2013	us-gaap	Officers Compensation OfficersCompensation	2788000	USD
CY2014	us-gaap	Officers Compensation OfficersCompensation	2249000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-20340000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-17167000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-19099000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	540000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	154000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	68000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	161000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	157000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	210000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	183000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	163000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	529000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	123000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	136000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	134000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	346000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-71000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-46000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-17008000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-16296000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-17496000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Writedown Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax	6000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Writedown Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax	0	USD
CY2014	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Writedown Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax	0	USD
CY2012	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	1606000	USD
CY2013	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	791000	USD
CY2014	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	665000	USD
CY2012	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	9000	USD
CY2013	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	800000	USD
CY2014	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	145000	USD
CY2012	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-9000	USD
CY2013	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-800000	USD
CY2014	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-145000	USD
CY2012	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	-6000	USD
CY2013	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	0	USD
CY2014	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	-2000	USD
CY2012	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	211000	USD
CY2013	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	242000	USD
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	258000	USD
CY2012	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	32765000	USD
CY2013	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8988000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-260319000	USD
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	358000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	399000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23003000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	249000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12817000	USD
CY2012	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	22658000	USD
CY2013	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	23479000	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3248000	USD
CY2012	us-gaap	Profit Loss ProfitLoss	-17354000	USD
CY2013	us-gaap	Profit Loss ProfitLoss	-16225000	USD
CY2014	us-gaap	Profit Loss ProfitLoss	-17450000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9387000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9601000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5053000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4601000	USD
CY2012	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	47000	USD
CY2013	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	45000	USD
CY2014	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	34000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9508000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8360000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-277769000	USD
CY2012	us-gaap	Revenues Revenues	213000	USD
CY2013	us-gaap	Revenues Revenues	150000	USD
CY2014	us-gaap	Revenues Revenues	197000	USD
CY2012	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	213000	USD
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	150000	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	197000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	0	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed	Black-Scholes-Merton
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	23003000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	249000	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12817000	USD
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	356000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	376000	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	326000	USD
CY2012	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	356000	USD
CY2013	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	376000	USD
CY2014	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	326000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	37965000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44700000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29298000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	25004000	USD
CY2012	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	331000	USD
CY2013	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-871000	USD
CY2014	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-191000	USD
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	141016935	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	167325584	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	188291976	shares
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hemispherx Biopharma, Inc. (“Company”) is a specialty pharmaceutical company headquartered in Philadelphia, Pennsylvania and engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. The Company was founded in the early 1970s doing contract research for the National Institutes of Health. Since that time, the Company has established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's flagship products include Alferon N Injection® and the experimental therapeutic Ampligen®. Alferon N Injection® is approved for a category of STD infection, and Ampligen® represents an experimental RNA being developed for globally important viral diseases and disorders of the immune system. Hemispherx' platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Alferon® LDO (Low Dose Oral) is a formulation under development targeting influenza.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the financial statements of Hemispherx Biopharma, Inc. and its wholly-owned subsidiaries. The Company has </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> domestic subsidiaries BioPro Corp., BioAegean Corp. and Core BioTech Corp., all of which are incorporated in Delaware and are dormant. The Company’s foreign subsidiary, Hemispherx Biopharma Europe N.V./S.A., was established in Belgium in 1998. All significant intercompany balances and transactions have been eliminated in consolidation. Certain items in these financial statements have been reclassified to conform to the current period presentation.</font></div></div>
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. Accounts requiring the use of significant estimates include valuation allowances for inventory, determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, stock-based compensation calculations, building valuation, fair value of warrants and contingency accruals.</font></div></div>

Files In Submission

Name	View Source	Status
0000946644-15-000008-index-headers.html	Edgar Link	pending
0000946644-15-000008-index.html	Edgar Link	pending
0000946644-15-000008.txt	Edgar Link	pending
0000946644-15-000008-xbrl.zip	Edgar Link	pending
a1024-armadabioridge1.htm	Edgar Link	pending
a1025-emergehemispherxagre.htm	Edgar Link	pending
emergehebagree_image1a01.gif	Edgar Link	pending
exhibit21-20141.htm	Edgar Link	pending
exhibit231-20141.htm	Edgar Link	pending
exhibit311-20141.htm	Edgar Link	pending
exhibit312-20141.htm	Edgar Link	pending
exhibit321-20141.htm	Edgar Link	pending
exhibit322-20141.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
heb-20141231.xml	Edgar Link	completed
heb-20141231.xsd	Edgar Link	pending
heb-20141231_cal.xml	Edgar Link	unprocessable
heb-20141231_def.xml	Edgar Link	unprocessable
heb-20141231_lab.xml	Edgar Link	unprocessable
heb-20141231_pre.xml	Edgar Link	unprocessable
heb1231201410k.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIM
AIM ImmunoTech Inc. Stock $aim

2015 Q1 Form 10-K Financial Statement

#000094664415000008 Filed on March 19, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM AIM ImmunoTech Inc. Stock $aim

2015 Q1 Form 10-K Financial Statement

#000094664415000008 Filed on March 19, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM
AIM ImmunoTech Inc. Stock $aim